Drugging KRAS: current perspectives and state-of-art review

Abstract After decades of efforts, we have recently made progress into targeting KRAS mutations in several malignancies. Known as the ‘holy grail’ of targeted cancer therapies, KRAS is the most frequently mutated oncogene in human malignancies. Under normal conditions, KRAS shuttles between the GDP-...

詳細記述

書誌詳細

出版年:	Journal of Hematology & Oncology
主要な著者:	Kaushal Parikh, Giuseppe Banna, Stephen V. Liu, Alex Friedlaender, Aakash Desai, Vivek Subbiah, Alfredo Addeo
フォーマット:	論文
言語:	英語
出版事項:	BMC 2022-10-01
オンライン･アクセス:	https://doi.org/10.1186/s13045-022-01375-4